Request Demo

Last update 27 Oct 2026

Ganciclovir

Last update 27 Oct 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol, 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one, 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one

+ [24]

Target

DNA polymerase

Action

inhibitors

Mechanism

DNA polymerase inhibitors(DNA polymerase inhibitors)

Therapeutic Areas

Infectious DiseasesEye DiseasesSkin and Musculoskeletal Diseases

Active Indication

Keratitis, HerpeticCytomegalovirus RetinitisCytomegalovirus Infections

Inactive Indication

Acquired Immunodeficiency SyndromeColitisHematopoietic stem cell transplantation+ [4]

Originator Organization

Syntex Corp.

Active Organization

Laboratoires Théa SAS

Hainan Poly Pharm. Co., Ltd.

Bausch & Lomb, Inc.

+ [4]

Inactive Organization

Exela Pharma Sciences LLC

CHEPLAPHARM Arzneimittel GmbHHoffmann-La Roche, Inc.

+ [4]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (23 Jun 1989),

Cytomegalovirus InfectionsCytomegalovirus Retinitis

RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea)

Structure/Sequence

Molecular FormulaC9H13N5O4

InChIKeyIRSCQMHQWWYFCW-UHFFFAOYSA-N

CAS Registry82410-32-0

146

Clinical Trials associated with Ganciclovir

NCT07513623

/ Not yet recruitingPhase 2IIT

Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II

The goal of this clinical trial is to compare antiviral treatment strategies for cytomegalovirus (CMV) anterior uveitis - a viral infection causing inflammation inside the front of the eye - in immunocompetent adults aged 18 years and older. The main questions it aims to answer are:
Does oral valganciclovir reduce aqueous humor CMV viral load more effectively than topical ganciclovir 2% eye drops or placebo after 7 days of treatment (Trial I)? Does long-term suppressive antiviral therapy (oral valganciclovir or topical ganciclovir 2% eye drops) reduce the rate of CMV anterior uveitis recurrence over 12 months compared to placebo (Trial II)?
Researchers will compare oral valganciclovir, topical ganciclovir 2% eye drops, and placebo to see if either antiviral treatment reduces viral load and controls eye inflammation more effectively in the short term, and whether long-term antiviral suppression can prevent the disease from coming back after the inflammation has been controlled.
Participants will:
* Undergo anterior chamber paracentesis (removal of a small amount of fluid from the front of the eye) for PCR testing to confirm CMV as the cause of their eye inflammation before enrollment
* Be randomly assigned to receive oral valganciclovir 900 mg twice daily, topical ganciclovir 2% eye drops six times daily, or placebo for 7 days (Trial I), in addition to standard steroid eye drops
* Return for follow-up visits at Day 7 and Day 21 for eye examinations, laboratory blood tests, and a second anterior chamber paracentesis at Day 7 to measure viral load after treatment
* If eye inflammation is controlled after Trial I, be offered enrollment into Trial II, where they will be randomly assigned to long-term suppressive oral valganciclovir, topical ganciclovir 2% eye drops, or placebo for 12 months, with follow-up visits approximately every 2 months and additional visits if inflammation returns

Start Date01 Nov 2026

Sponsor / Collaborator

The University of California, San Francisco

[+2]

NCT07450365

/ Not yet recruitingPhase 4IIT

Evaluation of Long-term Efficacy of 4 to 6-month Course Antiviral Therapy for Neurodevelopmental Impairments Caused by Congenital Cytomegalovirus Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical Trial

Title: Evaluation of Long-term Efficacy of 4-month versus 6-month Course Antiviral Therapy for Neurodevelopmental Impairment Caused by Congenital CMV Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical Study
1. Background and Rationale：Congenital cytomegalovirus (cCMV) infection is a leading cause of childhood neurodevelopmental disability and sensorineural hearing loss (SNHL). International guidelines, based on evidence from high-income countries, recommend a 6-month antiviral course for symptomatic infection. However, clinical practice in China lags significantly, still adhering to a 3-4 week regimen due to a lack of high-quality domestic evidence. Preliminary data suggest a 4-month course may be non-inferior to the 6-month standard by potentially aligning with the transition from productive to latent infection around 4 months of age. This study aims to address this critical evidence gap.2. Study Objectives：Primary: To evaluate the impact of intermediate (4-month) versus long (6-month) course antiviral therapy on long-term neurodevelopmental outcomes in infants with moderate-to-severe cCMV infection, and to establish a novel diagnostic and therapeutic framework.Secondary: To identify high-risk factors associated with adverse long-term outcomes.3. Study Design and Methods：This is a prospective, multicenter, randomized, open-label, parallel-controlled, non-inferiority clinical trial.Participants: Newborns (≤30 days old) diagnosed with moderate-to-severe cCMV infection. Key exclusion criteria include gestational age <32 weeks, birth weight <1.8 kg, and coexisting genetic/metabolic diseases.Randomization & Intervention: Eligible subjects will be block-randomized 1:1 via a computer-generated sequence.Experimental Group: Receives 4 months of antiviral therapy.Control Group: Receives 6 months of antiviral therapy (current international standard).Both groups receive either intravenous ganciclovir (6 mg/kg, twice daily) or oral valganciclovir (16 mg/kg, twice daily).Sample Size: A total of 150 subjects will be enrolled (60 from the lead center), anticipating 126 evaluable cases at study completion (2 years of age) to demonstrate non-inferiority with a margin (Δ) of 20%, 80% power, and a one-sided alpha of 0.025.4. Evaluation and Endpoints：Primary Outcome: Composite poor neurodevelopmental outcome at 12 months of age, defined as (1) death, or (2) moderate/severe impairment, including cerebral palsy, epilepsy, moderate-to-severe SNHL (>40 dB threshold and/or requiring cochlear implantation), visual impairment, or a score <-2 SD on standardized developmental scales (Griffiths, BSID-II, or Bayley-III).Secondary Outcomes: Include mild neurodevelopmental impairment at 12 months, and poor/mild neurodevelopmental outcomes at 24 months.Assessments: Scheduled follow-ups include clinical, laboratory (hepatic/renal function, CMV DNA load), and instrumental evaluations (neuroimaging, audiology, ophthalmology) during treatment and at 6, 12, and 24 months of age.5. Data Management and Ethics：Data will be managed using a multicenter Electronic Data Capture (EDC) system with double data entry. The study protocol has been approved by the Medical Ethics Committee of Children's Hospital, Zhejiang University School of Medicine. Written informed consent will be obtained from all participants' guardians. The study is scheduled from January 2026 to December 2028.This study will provide crucial high-level evidence to inform optimal antiviral therapy duration for cCMV infection in China, with the goal of improving long-term child health outcomes and reducing disease burden.

Start Date15 Feb 2026

Sponsor / Collaborator

The Children's Hospital of Zhejiang University School of Medicine

[+4]

ChiCTR2600118780

/ SuspendedNot ApplicableIIT

Start Date01 Jan 2026

Sponsor / Collaborator

The Children's Hospital of Zhejiang University School of Medicine

100 Clinical Results associated with Ganciclovir

100 Translational Medicine associated with Ganciclovir

100 Patents (Medical) associated with Ganciclovir

7,398

Literatures (Medical) associated with Ganciclovir

01 Dec 2026·POULTRY SCIENCE

In vivo evidence for FOXO3-mediated suppression of primordial follicle activation in chickens

Article

Author: Lu, Yangqing ; Lan, Meiyu ; Yang, Yaoyan ; Jia, Xiaoxuan ; Ji, Na ; Ran, Mingxia ; Peng, Rui ; Liu, Xingting ; Pu, Liping

Primordial follicle activation is a critical determinant of female reproductive lifespan. Although forkhead box O3 (FOXO3) conservatively regulates primordial follicle dormancy in mammals, its role in avian species remains unknown. Using the herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV)-mediated germ cell ablation system, we generated germline chimeric chickens carrying FOXO3-overexpressing (OE-FOXO3) primordial germ cells (PGCs). Overexpression was confirmed by RT-qPCR and Western blot. Compared with WT, OE-FOXO3 PGCs showed inhibited proliferation but retained germline identity and migration. In vivo, OE-FOXO3 chimeras exhibited delayed primordial follicle activation. Quantitative follicle staging at 3, 4, 7, and 21 days post-hatch (dph) revealed that OE-FOXO3 ovaries consistently maintained a higher proportion of primordial follicles and fewer growing follicles. By 21 dph, this difference was most evident: OE-FOXO3 follicles remained dormant with sustained nuclear/perinuclear FOXO3, whereas control follicles progressed, showing cytoplasmic or peripheral granulosa cell FOXO3 staining. At 3 dph, OE-FOXO3 ovaries contained fewer germ cell clusters and reduced apoptosis. By 4 dph, coinciding with the onset of primordial follicle activation, Western blot analysis revealed that the PI3K/AKT signaling was significantly activated in the control ovaries, whereas this activation was suppressed in the OE-FOXO3 ovaries. Collectively, these findings provide the first in vivo evidence that FOXO3 functions as a negative regulator of primordial follicle activation in chickens. Notably, this suppressed activation state was associated with reduced PI3K/AKT signaling. This study extends the functional conservation of FOXO3 beyond mammals, offering new insights into avian ovarian reserve establishment.

01 Nov 2026·ANTIVIRAL RESEARCH

Antiviral activity of amenamevir alone and in combination with ganciclovir against equine herpesvirus 1

Article

Author: Tsujimura, Koji ; Bannai, Hiroshi ; Barnoux, Thomas ; Kambayashi, Yoshinori ; Fortier, Christine ; Pronost, Stéphane ; Nemoto, Manabu ; Fortier, Guillaume ; Hue, Erika S ; Kawanishi, Nanako ; Normand, Camille

Equine herpesvirus 1 (EHV-1) causes respiratory disease, abortion, and equine herpesvirus myeloencephalopathy (EHM), a neurological disorder characterized by ataxia and hindlimb paralysis. Although EHM remains a major concern in the equine industry, effective antiviral treatment options are limited. This study evaluated the antiviral activity of amenamevir, a helicase-primase complex inhibitor, against multiple EHV-1 strains using real-time cell analysis (RTCA) and quantitative PCR (qPCR), and compared its potency with those of ganciclovir, acyclovir, and penciclovir. Eight EHV-1 strains associated with different clinical manifestations and characterized by A, G, or C at position 2254 of open reading frame 30, which encodes the viral DNA polymerase, were examined. RTCA-based half-maximal inhibitory concentration (IC₅₀) values were calculated from inhibition rates based on the area under the normalized cell index curve. Across the eight strains, IC₅₀ values were 0.45-2.31 μg/mL for amenamevir, 0.45-3.95 μg/mL for ganciclovir, 17.93-50.15 μg/mL for acyclovir, and 8.38-24.52 μg/mL for penciclovir. qPCR analysis, based on concentrations required to achieve a 1-log₁₀ reduction in viral genome copy number, showed a similar overall trend. Amenamevir exhibited in vitro antiviral activity against EHV-1, with potency comparable to that of ganciclovir and greater than those of acyclovir and penciclovir. SynergyFinder analysis showed synergistic interactions between amenamevir and ganciclovir within selected concentration ranges against EHV-1 strains in both the Bliss independence and ZIP models. These findings support further investigation of amenamevir, alone and in combination with ganciclovir, as a candidate antiviral compound for the treatment of EHV-1 infection.

01 Nov 2026·ANTIVIRAL RESEARCH

Inhibition of Porcine Cytomegalovirus/Porcine Roseolovirus (PCMV/PRV) replication with antiviral compounds

Article

Author: Arav-Boger, R ; Yamada, K ; Eisenson, D ; Avery, R ; Mei, H ; Chelladurai, A ; Atkinson, S N

The global organ shortage has driven significant interest in xenotransplantation, accelerated by advances in immunology and genetic engineering. However, infectious complications and immune responses remain incompletely understood. Porcine cytomegalovirus/porcine roseolovirus (PCMV/PRV) is endemic in pigs and has been transmitted to xenotransplant recipients, where it may contribute to graft dysfunction. We evaluated FDA-approved and investigational antivirals against PCMV/PRV replication in vitro using plaque assays and quantitative PCR (qPCR) of the PCMV/PRV polymerase. The most efficacious agents by qPCR were DNA polymerase inhibitors brincidofovir (EC₅₀ 0.01 μM), cidofovir (EC₅₀ 1.65 μM), cyclopropavir (EC₅₀ 2.13 μM), and oxazolidinone amide derivatives (EC₅₀ 1-3 μM); hPMPA was also active (EC₅₀ 8.37 μM). Ganciclovir showed reduced activity compared to Human CMV (HCMV, EC₅₀ 18.07 μM), and foscarnet EC₅₀ was 93.64 μM. FDA-approved antivirals acyclovir, maribavir, and letermovir were inactive or showed reduced activity compared to their anti-HCMV activity. The investigational drug pritelivir was also inactive. Two investigational HCMV inhibitors, MLS8554 and MLS8091, inhibited PCMV/PRV. Antiviral anticellular agents artesunate, artemisinin dimer 838, emetine, and digitoxin inhibited PCMV/PRV at concentrations comparable to HCMV inhibition. Emetine (EC₅₀ 0.03 μM) and digitoxin (EC₅₀ 0.010 μM) were the most potent. Artesunate was additive when combined with active PCMV/PRV inhibitors. This extensive investigation reveals a PCMV/PRV inhibition pattern similar to that of HHV-6. Although several compounds showed in vitro activity, their clinical utility must be weighed against toxicity at effective concentrations. Additional studies are needed to identify effective antivirals for PCMV/PRV and to optimize drug combination strategies.

News (Medical) associated with Ganciclovir

22 Oct 2026

·www.prnewswire.com

Rznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission

SEONGNAM, South Korea, Oct. 22, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec(RZ-001)', its RNA-editing gene therapy for the treatment of glioma. The designation follows the positive opinion adopted in September 2026 by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency's (EMA). This marks RZ-001's first regulatory designation in Europe and further strengthens its development foundation across the two major markets of the United States and Europe. Orphan Medicinal Product Designation is intended to encourage the development of medicines for rare, serious, or life-threatening conditions. The program offers regulatory and development benefits, including the possibility of market exclusivity following approval, reduced development fees, and support to enhance clinical development efficiency for orphan drugs. "Following its designation in the United States, RZ-001's orphan designation in Europe provides further positive momentum for its development," said Bomi Kim, Head of the Drug Development Center at Rznomics. "Building on this milestone, we will continue to communicate the value of RZ-001 to potential global partners." "Glioblastoma has a poor prognosis and remains an area of significant unmet medical need," added Dr. Seong-Wook Lee, CEO of Rznomics. "With the European Commission's orphan designation of RZ-001, we will continue our efforts to develop RZ-001 as a potential new treatment option for patients with difficult-to-treat cancers." RZ-001 has also secured several regulatory designations from the U.S. Food and Drug Administration (FDA), supporting its development prospects and potential partnering value. The FDA has granted Orphan Drug Designation (ODD) and Fast Track designation for RZ-001 for treatment of hepatocellular carcinoma (HCC) and glioblastoma (GBM). In addition, RZ-001 received Regenerative Medicine Advanced Therapy (RMAT) designation for HCC in May 2026. Rznomics aims to advance global partnerships and expand the commercial potential of RZ-001. In addition to HCC and GBM, which are currently under clinical development, the company is pursuing expansion into additional solid tumor indications. About Glioblastoma (GBM) Glioblastoma is the most common and aggressive primary malignant brain tumor in adults, classified as a WHO Grade IV tumor. Characterized by rapid progression, high recurrence rates, and resistance to standard therapies, recurrent glioblastoma remains an area of significant unmet medical need with limited effective therapeutic options available globally. About Orphan Medicinal Product Designation in the European Union Orphan Medicinal Product Designation in the European Union is intended to encourage the development of medicines for rare, serious, or life-threatening conditions. Designated products may benefit from regulatory incentives, including protocol assistance and fee reductions. Following marketing authorization, eligible products may receive ten years of market exclusivity, which may be extended to twelve years in certain circumstances. The EU orphan designation assessment considers several factors, including the rarity and severity of the disease, the rationale for developing the medicinal product, and the availability of existing treatments. Where approved treatment methods already exist, evidence supporting the potential for the investigational product to provide a "significant benefit" to patients is an important consideration. How RZ-001 (taspitimagene advec) Works RZ-001 utilizes Rznomics' proprietary RNA trans-splicing ribozyme technology. The ribozyme embedded in RZ-001 selectively recognizes and cleaves hTERT mRNA expressed in cancer cells, replacing it with an RNA strand containing a suicide gene (HSV-TK) derived from the herpes simplex virus. Subsequently, the orally administered antiviral prodrug valganciclovir, is converted to ganciclovir and further activated by HSV-TK, generating cytotoxic metabolites that inhibit viral and cellular DNA synthesis and selectively induce apoptosis in cancer cells. About Rznomics Inc. Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies. The company's proprietary trans-splicing ribozyme platform enables precise RNA editing and has broad applicability across multiple indications. The company signed a research collaboration and license agreement with the global pharmaceutical company Eli Lilly in May 2025 for the development of a novel RNA editing therapeutic and listed on the KOSDAQ market in December 2025. (KOSDAQ 476830) For more information, please visit SOURCE Rznomics 21% more press release views with Request a Demo

Orphan DrugLicense out/inClinical StudyGene Therapy

30 Sep 2026

·www.prnewswire.com

Rznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for Glioma

SEONGNAM, South Korea, Sept. 30, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the Orphan Medicinal Product Designation (OMPD) for RZ-001 (taspitimagene advec) for the treatment of glioma. RZ-001 is an adenovirus serotype 5-vectored gene therapy built on Rznomics' proprietary RNA trans-splicing ribozyme platform. It targets human telomerase reverse transcriptase (hTERT) mRNA—overexpressed in 80–90% of human cancers—and replaces the target RNA with a therapeutic RNA encoding the cytotoxic herpes simplex virus thymidine kinase (HSV-TK), thereby selectively inducing apoptosis in cancer cells. This recommendation was grounded in a Phase 1/2a interim clinical data from patients with recurrent glioblastoma (GBM), a subtype of glioma and a highly aggressive WHO Grade IV brain cancer associated with a 1-year survival rate of less than 25%. Despite existing authorized therapies in Europe, the COMP determined that RZ-001 has sufficient potential to provide a "significant benefit". RZ-001 is currently being evaluated in a Phase 1/2a clinical trial in South Korea (IND clearance in the U.S.) for patients with hTERT-positive recurrent GBM, and has been administered to 10 patients enrolled in clinical trials and to 3 patients under the U.S. FDA's Expanded Access Program. "This positive opinion from the EMA COMP shows that RZ-001 goes beyond meeting basic prevalence criteria by delivering meaningful, evidence-backed clinical advantages over current standard-of-care treatments for glioma," said Bomi Kim, Head of the Drug Development Center at Rznomics. "We will continue to advance our global regulatory and clinical development roadmap." "Following our FDA RMAT designation for hepatocellular carcinoma (HCC) in May 2026, this European regulatory recognition further strengthens the therapeutic versatility and commercial potential of our RNA editing platform," added Dr. Seong-Wook Lee, CEO of Rznomics. "We are committed to expanding RZ-001's target indications and accelerating global business development opportunities." Following formal designation by the European Commission, Rznomics will be eligible for key regulatory and commercial incentives, including up to 10 years of market exclusivity, EMA protocol assistance, and reductions in regulatory and filing fees associated with European marketing applications. About Glioblastoma (GBM) Glioblastoma is the most common and aggressive primary malignant brain tumor in adults, classified as a WHO Grade IV tumor. Characterized by rapid progression, high recurrence rates, and resistance to standard therapies, recurrent glioblastoma remains an area of significant unmet medical need with limited effective therapeutic options available globally. About Orphan Medicinal Product Designation in the European Union Orphan Medicinal Product Designation in the European Union is granted to medicinal products for the treatment of rare, serious, or life-threatening conditions and provides regulatory incentives, including ten years of market exclusivity following approval, which may be extended to twelve years in certain circumstances. How RZ-001 (taspitimagene advec) Works RZ-001 utilizes Rznomics' proprietary RNA trans-splicing ribozyme technology. The ribozyme embedded in RZ-001 selectively recognizes and cleaves hTERT mRNA expressed in cancer cells, replacing it with an RNA strand containing a suicide gene (HSV-TK) derived from the herpes simplex virus. Subsequently, the orally administered antiviral prodrug valganciclovir, is converted to ganciclovir and further activated by HSV-TK, generating cytotoxic metabolites that inhibit viral and cellular DNA synthesis and selectively induce apoptosis in cancer cells. About Rznomics Inc. Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies. The company's proprietary trans-splicing ribozyme platform enables precise RNA editing and has broad applicability across multiple indications. The company signed a research collaboration and license agreement with the global pharmaceutical company Eli Lilly in May 2025 for the development of a novel RNA editing therapeutic and listed on the KOSDAQ market in December 2025. (KOSDAQ 476830) For more information, please visit SOURCE Rznomics 21% more press release views with Request a Demo

Clinical StudyLicense out/inOrphan DrugGene TherapyIND

30 Apr 2026

·www.rohto.co.jp

Notice of Manufacturing and Marketing Approval Application for "ROH-101 (Ganciclovir Eye Drops Gel)," a Treatment for Cytomegalovirus Corneal Endotheliitis

ROHTO Pharmaceutical Co., Ltd. (Head office: Osaka City, President: Hidetoshi Segi, hereinafter "Rohto Pharmaceutical") is pleased to announce that it has submitted an application for manufacturing and marketing approval in Japan on April 30, 2026, for "Development code ROH-101 (Ganciclovir eye drops gel)" (hereinafter, "this product"), a treatment for cytomegalovirus keratitis.

100 Deals associated with Ganciclovir

External Link

KEGG	Wiki	ATC	Drug Bank
D00333	Ganciclovir	J05AB06 S01AD09	DB01004

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Keratitis, Herpetic	United States	Bausch & Lomb, Inc.	15 Sep 2009
Cytomegalovirus Infections	United States	CHEPLAPHARM Arzneimittel GmbH	23 Jun 1989
Cytomegalovirus Retinitis	United States	CHEPLAPHARM Arzneimittel GmbH	23 Jun 1989

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematopoietic stem cell transplantation	Phase 3	Austria	Roche Pharma AG	01 Sep 2010
Hematopoietic stem cell transplantation	Phase 3	Germany	Roche Pharma AG	01 Sep 2010
Hematopoietic stem cell transplantation	Phase 3	Spain	Roche Pharma AG	01 Sep 2010
Acquired Immunodeficiency Syndrome	Phase 3	United States	-	31 Aug 2001
HIV Infections	Phase 3	United States	Hoffmann-La Roche, Inc.	01 Jan 1997
HIV Infections	Phase 3	Canada	Hoffmann-La Roche, Inc.	01 Jan 1997
Keratoconjunctivitis, Infectious	Phase 2	France	Laboratoires Théa SAS	01 Mar 2009
Immunosuppression	Phase 2	United States	Hoffmann-La Roche, Inc.	31 Aug 2001
Stomach Diseases	Phase 2	United States	Hoffmann-La Roche, Inc.	31 Aug 2001
Colitis	Phase 1	United States	Hoffmann-La Roche, Inc.	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03586284 (STACCATO, CTgov)	Phase 2/3	Uveitis, Anterior	51	Topical placebo+Valganciclovir Hydrochloride (Oral Valganciclovir)	upavyumtql(wjhtidrhia) = qfscqgsbye rvmwbopgem (ubqkqlpnbk, 0.87) View more	-	10 Feb 2026
				Placebo Oral Tablet+Ganciclovir Sodium (Topical Ganciclovir 2%)	upavyumtql(wjhtidrhia) = tvrgojjjkm rvmwbopgem (ubqkqlpnbk, 0.59) View more
NCT04706507 (GRAIL^3, CTgov)	Phase 3	Respiratory Failure \| Sepsis	205	IV Ganciclovir (IV Ganciclovir)	fuszxsvgpk(vzcxzckxfj) = ratxxksfqb uwpkswqzip (hgtpsrieyi, 11.1) View more	-	12 Dec 2025
				Normal saline (Placebo)	fuszxsvgpk(vzcxzckxfj) = bzktobepcg uwpkswqzip (hgtpsrieyi, 10.9) View more
EURETINA2025	Not Applicable	Cytomegalovirus Retinitis	1	Intravitreal Foscarnet + Systemic Ganciclovir/Valganciclovir + Anti-VEGF (Aflibercept) + Topical Corticosteroids	pclugoobaq(wcvqwnkqgr) = Transient ocular hypertension (IOP: 25 mmHg) post- injection, managed with topical timolol. Cystoid macular edema in OS (GMC: 242 μm) resolved after 3 monthly aflibercept injections. ftevwfqdqa (ooilsujloo ) View more	Positive	04 Sep 2025
ECCO2025	Not Applicable	Cytomegalovirus Infections	8	Valganciclovirganciclovir or ganciclovir	nvywchqwsc(vilnrdrfsb) = hwquifddti haaybkfrab (rncsjdlfqs )	Positive	19 Feb 2025
EBMT2024	Not Applicable	Cytomegalovirus Infections	31	ganciclovir	wtaabbqieu(fzsshjljbq) = thrombocytopenia and neutropenia were the most common types, each occurring in a total of 6 (19.4%) patients. Of patients with myelosuppression, 6 (54.5%), 3 (27.3%), and 2 (18.2%) were receiving ganciclovir, foscarnet, or valganciclovir, respectively. Overall, 8 (25.8%) patients experienced a nephrotoxicity event during index CMV episodes; these patients were receiving foscarnet (5 [62.5%] patients), ganciclovir (1 [12.5%] patient), valganciclovir (1 [12.5%] patient), or dual therapy (1 [12.5%] patient). fhnmysacjg (wiazueneqo )	Negative	14 Apr 2024
Tandem Meetings ASTCT and CIBMTR2023	Not Applicable	Cytomegalovirus Infections	-	Ganciclovir/Valganciclovir	ugcixinqjo(flprlogkeg) = exyabknuvb ttbawzfqpz (ujluilugsi )	Positive	01 Feb 2023
				Letermovir	ugcixinqjo(flprlogkeg) = tcfetoiizj ttbawzfqpz (ujluilugsi )
Tandem Meetings ASTCT and CIBMTR2022	Not Applicable	Hematopoietic stem cell transplantation	-	Ganciclovir prophylaxis through day +100	iekychkdem(tgulrqgidd) = qzxwavqdvu tccpniyxvr (ajycpoblzi, 0 - 71.3) View more	Negative	01 Mar 2022
				Alternative CMV prophylaxis prior to day +100	iekychkdem(tgulrqgidd) = dazuwbattf tccpniyxvr (ajycpoblzi, 19.4 - 66.9) View more
NCT02382588 (CTgov)	Phase 2	Keratitis, Herpetic	8	gancyclovir gel (Gancyclovir Gel)	jxtokarbyt(yxxjxnuykv) = bvulwcyqwd rwxnjrchwx (obbrgxgeoq, adzeheoleo - thuilsjyky) View more	-	08 Jul 2021
				Hypromellose gel (Hypromellose Gel)	jxtokarbyt(yxxjxnuykv) = qhdajaeknw rwxnjrchwx (obbrgxgeoq, yymtfwwkkj - glggzrznlp) View more
Tandem Meetings ASTCT and CIBMTR2021	Not Applicable	Hematopoietic stem cell transplantation	-	Ganciclovir prophylaxis through day +100	sepoxquwbg(dplzhvejxz) = ywegmpwywb usqikubqwy (umwfccmziz, 13.0 - 59.4) View more	-	01 Mar 2021
				Ganciclovir (No CMV viremia/disease)	sepoxquwbg(dplzhvejxz) = zzjnaawlor usqikubqwy (umwfccmziz, 62.3 - 82.9) View more
Tandem Meetings ASTCT and CIBMTR2019	Not Applicable	-	-	Ganciclovir pretransplant	lkgxvzysej(rfuigbjwpg) = dbknhovwon ajsfjfyasp (lagmndpirr, 18% - 37%)	-	01 Mar 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis